Loading...
High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.
Chow, Shien Galvis, Victoria Pillai, Manon Leach, Rebecca Keene, Elizabeth Spencer-Shaw, Andrea Shablak, Alaaeldin Shanks, Jonathan H Liptrot, Tom
Chow, Shien
Galvis, Victoria
Pillai, Manon
Leach, Rebecca
Keene, Elizabeth
Spencer-Shaw, Andrea
Shablak, Alaaeldin
Shanks, Jonathan H
Liptrot, Tom
Citations
Altmetric:
Abstract
VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective immunotherapy treatment capable of durable remission in some patients but its unselected use has been difficult due to its modest response rate and considerable adverse effects. Using set pathology criteria as a selection tool in clinical practice, we have been able to show improved outcomes in our previous report. Here, we present an updated and extended report of this treatment and seek to explore any pathological, clinical and treatment variables likely to predict better outcomes.
Affiliation
Description
Date
2016
Publisher
Collections
Files
Keywords
Type
Article
Citation
High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. 2016, 4:67 J Immunother Cancer